Familial hypercholesterolemia is one of the most clinically relevant monogenic disorders contributing to the development of atherosclerotic cardiovascular disease.
The setting of a target low-density lipoprotein cholesterol level below 70 mg/dL in the 5 years following an ischemic stroke was associated with a 25% reduction in intracranial hemorrhages.
The combination of higher serum oxidized low-density lipoprotein (oxLDL) and LDL levels was found to be associated with an increased risk for recurrent stroke and poor functional outcomes in patients who have had minor stroke or are at high risk for transient ischemic attacks.
Individuals with monogenic or polygenic familial hypercholesterolemia were found to be at an elevated risk of atherosclerotic cardiovascular disease compared with those with nongenetic hypercholesterolemia.
Patients with dyslipidemia and type 1 diabetes with high vs low adherence to lipid-lowering therapy were found to be at lower risk for nonfatal cardiovascular disease.
Excess adiposity, increasingly a worldwide pathological condition, represents a major risk factor for most chronic diseases, including colorectal cancer.
Nexlizet will be available as 180mg bempedoic acid/10mg ezetimibe tablets in 30- and 90-count bottles in July 2020; Nexletol will be available on March 30, 2020.
Machine learning identifies factors related to obesity, dyslipidemia, and inflammation as predictors of noncalcified coronary burden in patients with psoriasis, a study finds.
